F8 and hemophilia A: In addition, while AAV-cfVIII gene therapy in canine models of hemophilia A results in a heterogenic immune response that more closely resembles what is observed clinically, wild type NHPs uniformly generate a robust humoral immune response to human fVIII following AAV-hfVIII gene therapy.